<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>2001 (5) TMI 91 - CEGAT, MUMBAI</title>
    <link>https://www.taxtmi.com/caselaws?id=50543</link>
    <description>Classification of medicaments under Chapter 30 depends on whether the label bears a non-pharmacopoeial name, brand name or invented word indicating a trade connection. Products displaying only generic names, or prominently displaying the generic ingredient name with a coined name only secondarily, are not patent or proprietary medicaments and fall under the residual category of other medicaments. This classification disentitles the manufacturer to Modvat credit on inputs used in manufacture. Penalty is warranted where generic labelling and the absence of distinguishing marks do not reasonably support the claimed patent or proprietary medicament classification.</description>
    <language>en-us</language>
    <pubDate>Thu, 17 May 2001 00:00:00 +0530</pubDate>
    <lastBuildDate>Mon, 23 Aug 2010 12:52:36 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=89023" rel="self" type="application/rss+xml"/>
    <item>
      <title>2001 (5) TMI 91 - CEGAT, MUMBAI</title>
      <link>https://www.taxtmi.com/caselaws?id=50543</link>
      <description>Classification of medicaments under Chapter 30 depends on whether the label bears a non-pharmacopoeial name, brand name or invented word indicating a trade connection. Products displaying only generic names, or prominently displaying the generic ingredient name with a coined name only secondarily, are not patent or proprietary medicaments and fall under the residual category of other medicaments. This classification disentitles the manufacturer to Modvat credit on inputs used in manufacture. Penalty is warranted where generic labelling and the absence of distinguishing marks do not reasonably support the claimed patent or proprietary medicament classification.</description>
      <category>Case-Laws</category>
      <law>Central Excise</law>
      <pubDate>Thu, 17 May 2001 00:00:00 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/caselaws?id=50543</guid>
    </item>
  </channel>
</rss>